Abstracts tagged "galectin and systemic lupus erythematosus (SLE)"

Abstract Number: 694 • 2017 ACR/ARHP Annual Meeting
Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity
Sung Soo Ahn¹, Younhee Park², Seung Min Jung¹, Jason Jungsik Song¹, Yong-Beom Park¹ and Sang-Won Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Abstract Background/Purpose : Serum Mac-2-binding protein (M2BP) is elevated in various chronic inflammatory diseases. Recently, the Wisteria floribunda agglutinin positive-M2BP (WFA+-M2BP) immunoassay has shown promise…
Abstract Number: 1860 • 2015 ACR/ARHP Annual Meeting
Autoantibodies Utilizing the Immunoglobulin Heavy Chain Variable Region Gene 4-34 (VH4-34) Exhibit Autoreactivity Towards, and Potential Competition with Galectins within Systemic Lupus Erythematosus (SLE)
Kevin Cashman¹, Asiya Chida² and Ignacio Sanz², ¹Department of Medicine- Division of Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by the propagation of autoreactive B cell populations leading to the production of pathogenic antibodies…
Abstract Number: 1633 • 2014 ACR/ARHP Annual Meeting
Galectin-3-Binding Protein Is Associated with Disease Activity, but Not with Atherosclerosis in SLE Patients
Susan Kay¹, Niels Heegaard² and Anne Voss³, ¹Rheumatolog, Rheumatology, Odense, Denmark, ²Cinical Biochemistry and Pharmacology, Cinical Biochemistry and Pharmacology, Odense, Denmark, ³Reumatology, Reumatology, Odense, Denmark
Background/Purpose . Patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD), which may be due to an increased prevalence of atherosclerosis.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].